title: Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients.
abstract: OBJECTIVE
  The objectives of this study were to determine whether peripheral blood mononuclear cell (PBMC)-associated HIV-1 DNA level in patients on long-term suppressive antiretroviral therapy (ART) was associated with plasma HIV-1 RNA level, CD4 cell count, and therapeutic factors throughout patient history.
  
  
  METHODS
  Patients receiving triple or dual therapy with plasma HIV-1 RNA below detection limit for more than 3 years were recruited in a multicentric, cross-sectional study within the eight virology laboratories of the Agence Nationale de Recherche sur le SIDA et les Hépatites virales HIV quantification working group, each one in relation with a clinical center.
  
  
  METHODS
  PBMC-associated HIV-1 DNA was quantified using a standardized real-time PCR method in all laboratories.
  
  
  RESULTS
  A total of 236 patients was included. Median HIV-1 DNA was 2.8 log10 copies/10 PBMCs (interquartile range 2.4-3.0). Univariate analysis showed PBMC HIV-1 DNA level to be related to pre-ART immuno-virologic status (plasma HIV-1 RNA zenith and CD4 cell count nadir) and to current CD4 T-cell count. HIV-1 DNA was lower in patients receiving ART with inferior virologic efficacy, as they also had a higher CD4 nadir and a lower HIV-1 RNA zenith than other patients. PBMC HIV-1 DNA level was not related to therapy duration, to time spent with undetectable HIV-1 RNA or to occurrence of a blip. Plasma HIV-1 RNA zenith and CD4 cell count nadir remained predictive of HIV-1 DNA level in the multivariate model which was associated with 22% of its variability.
  
  
  CONCLUSIONS
  Whatever the duration of treatment, HIV-1 DNA level during ART gives a picture of the intensity of viral replication and immune deficiency reached before starting therapy.
authors: Laboratoire de Virologie, CHU Necker-Enfants Malades, AP-HP, Paris, France. marianne.burgard@nck.aphp.fr
authors: Marianne
authors: M
authors: Burgard
authors: Faroudy
authors: F
authors: Boufassa
authors: Jean-Paul
authors: JP
authors: Viard
authors: Isabelle
authors: I
authors: Garrigue
authors: Annick
authors: A
authors: Ruffault
authors: Jacques
authors: J
authors: Izopet
authors: Astrid
authors: A
authors: Vabret
authors: Diane
authors: D
authors: Descamps
authors: Philippe
authors: P
authors: Colson
authors: Jean-Marie
authors: JM
authors: Seigneurin
authors: Christine
authors: C
authors: Rouzioux
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003430:Cross-Sectional Studies; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents; D004279:DNA, Viral; D012367:RNA, Viral